This Week in Aesthetics: May 10-14

This week in aesthetics, a new survey quantifies the QoL data for transmen post gender-affirming surgery, a study examines abdominal contouring using HIFEM and RF combination therapy, Allergan Aesthetics announces the acquisition of Soliton, a comparative study looks at laser comparisons in keloid management, a study details cetirizine 1% cream for androgenetic alopecia, and Ava Shamban, MD, discusses microneedling differentiators using the Vivace Microneedle RF device.

Psychosocial Benefits of Gender Affirming Surgery

A new survey from the University of California is the first to quantify the quality-of-life data for transgender men who undergo gender-affirming surgery.

Abdominal Contouring Using HIFEM and RF Combination Therapy

A recent study looks at the safety and efficacy of HIFEM and RF combination therapy for fat reduction.

Allergan Acquires Soliton Following Launch of RAP Device

Allergan Aesthetics, an AbbVie company, announces the acquisition of Soliton and its newly launched RAP device, further expanding the company’s body contouring portfolio.

Laser Comparison in Keloid Management

A comparative study examines Fractional CO2 and Nd‐YAG laser effectiveness in keloid management.

Cetirizine 1% Cream for Androgenetic Alopecia

A recent study examined cetirizine 1% cream as treatment in male patients diagnosed with androgenetic alopecia.

Microneedling Differentiators

Ava Shamban, MD, discusses microneedling differentiators using the Vivace Microneedle RF device, combination therapies, and the importance of social media partnerships.